CATB - Catabasis Pharmaceuticals, Inc.
| Previous Close | 5.31 |
| Open | 5.35 |
| Bid | 5.33 x 1000 |
| Ask | 5.36 x 1000 |
| Day's Range | 5.28 - 5.35 |
| 52 Week Range | 3.60 - 9.76 |
| Volume | 13,018 |
| Avg. Volume | 80,676 |
| Market Cap | 62.997M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.58 |
| Earnings Date | Nov 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.00 |
- Thomson Reuters StreetEvents
Edited Transcript of CATB earnings conference call or presentation 7-Nov-19 1:30pm GMT
Q3 2019 Catabasis Pharmaceuticals Inc Earnings Call
- Business Wire
Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress
-- Edasalonexent Global Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Fully Enrolled with Top-Line Results Expected in Q4 2020 --
- Business Wire
Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, will report third quarter 2019 financial results before the Nasdaq Global Market open on Thursday, November 7, 2019.
- Simply Wall St.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB): When Will It Breakeven?
Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB): Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical...
- Business Wire
Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced that results from the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular dystrophy (DMD) will be presented at the Child Neurology Society 48th Annual Meeting to be held October 23-26 in Charlotte, North Carolina. Richard Finkel, M.D., Chief, Division of Neurology, Department of Pediatrics at Nemours Children’s Health System and a Principal Investigator for the Phase 2 MoveDMD and Phase 3 PolarisDMD studies of edasalonexent, will give an oral presentation titled “Treatment of Young Boys with Duchenne Muscular Dystrophy with the NF-kB Inhibitor Edasalonexent Showed a Slowing of Disease Progression as Assessed by MRI and Functional Measures” during Platform Session 1 on Friday, October 25th at 9:00am ET.
- Business Wire
Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today presented the findings from the MoveDMD trial of edasalonexent. In the Phase 2 MoveDMD trial and open-label extension, edasalonexent slowed disease progression compared to the off-treatment control period and was well tolerated through more than 55 cumulative patient years of exposure in boys affected by Duchenne muscular dystrophy (DMD). “Our goal is to provide a therapy for DMD that slows disease progression, has a compelling safety profile and can be used in boys regardless of mutation,” said Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis.
- Business Wire
Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, announced today the completion of enrollment for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD). Top-line results from the Phase 3 PolarisDMD trial are expected in the fourth quarter of 2020 and the trial is anticipated to support an NDA filing in 2021. At a time when there are multiple trials for Duchenne, we are very pleased that physicians and families chose the Phase 3 PolarisDMD trial for edasalonexent,” said Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis.
- Simply Wall St.
How Much Of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Do Institutions Own?
A look at the shareholders of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) can tell us which group is most powerful...
- Simply Wall St.
Investors Who Bought Catabasis Pharmaceuticals (NASDAQ:CATB) Shares Three Years Ago Are Now Down 87%
It's not possible to invest over long periods without making some bad investments. But you want to avoid the really...
- Thomson Reuters StreetEvents
Edited Transcript of CATB earnings conference call or presentation 8-Aug-19 12:30pm GMT
Q2 2019 Catabasis Pharmaceuticals Inc Earnings Call
- Simply Wall St.
Does Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) CEO Pay Reflect Performance?
Jill Milne became the CEO of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) in 2008. This analysis aims first to...
- Business Wire
Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, shared an update on the clinical development of edasalonexent, a novel NF-kB inhibitor for the treatment of Duchenne muscular dystrophy (DMD) this week at the Parent Project Muscular Dystrophy (PPMD) 25th Annual Conference. Screening is ongoing for the randomized, double-blind, placebo-controlled trial in the United States, Canada, Australia, the United Kingdom, Ireland, Sweden, Germany and Israel and making strong progress. Clinical trial sites globally are enrolling quickly and sites in the United Kingdom, Ireland, Sweden, Germany and Israel are at capacity and no longer accepting additional patients.
- Business Wire
Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today presented new preclinical data showing preserved bone health with edasalonexent in contrast to negative effects of the corticosteroid prednisolone in a mouse model of Duchenne muscular dystrophy (DMD). Edasalonexent is a novel NF-kB inhibitor in Phase 3 development for the treatment of DMD. The data were presented at the Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy.
- Business Wire
Catabasis Pharmaceuticals to Present at Upcoming Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and Parent Project Muscular Dystrophy 25th Annual Conference
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent, a novel NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy , at two upcoming meetings: the Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and the Parent Project Muscular Dystrophy 25th Annual Conference.
- Zacks
Vertex Expands Collaboration With CRISPR, Acquires Exonics
Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.
- Thomson Reuters StreetEvents
Edited Transcript of CATB earnings conference call or presentation 14-May-19 12:30pm GMT
Q1 2019 Catabasis Pharmaceuticals Inc Earnings Call
- GuruFocus.com
SV Life Sciences Advisers, LLC Buys Catabasis Pharmaceuticals Inc, Sells KalVista ...
Boston, MA, based Investment company SV Life Sciences Advisers, LLC buys Catabasis Pharmaceuticals Inc, sells KalVista Pharmaceuticals Inc, Avrobio Inc during the 3-months ended 2019Q1, according to the ...
- Business Wire
Catabasis Pharmaceuticals Reports First Quarter 2019 Financial Results and Reviews Business Progress
-- Edasalonexent Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Enrolling Boys Globally --
